166-180 of 813
Mapping Brain Atrophy in Schizophrenia
On the Frontlines of SchizophreniaMapping Brain Atrophy in Schizophrenia
Ahmed Makhlouf, MD
Aging and Multiple Sclerosis: Insights from the 2024 CMSC Consensus Statement
On the Frontlines of Multiple SclerosisAging and Multiple Sclerosis: Insights from the 2024 CMSC Consensus Statement
Charles Turck, PharmD, BCPS, BCCCP
Yinan Zhang, MD
Sarah A. Morrow, MD, MS, FRCPC, FAAN
MS Management: Strategies for Ensuring Equitable Access to Teleneurology
On the Frontlines of Multiple SclerosisMS Management: Strategies for Ensuring Equitable Access to Teleneurology
Marisa McGinley, DO
Managing MS in Older Adults: Key Considerations for DMTs and Lifestyle Interventions
On the Frontlines of Multiple SclerosisManaging MS in Older Adults: Key Considerations for DMTs and Lifestyle Interventions
Charles Turck, PharmD, BCPS, BCCCP
Kimberly DiMauro, DO
Carol Swetlik, MD
Understanding Schizophrenia: Early Intervention and Prevention Strategies
On the Frontlines of SchizophreniaUnderstanding Schizophrenia: Early Intervention and Prevention Strategies
Joseph F. Goldberg, MD
Optimizing Schizophrenia Care: Strategies for Managing Side Effects and Treatment Resistance
On the Frontlines of SchizophreniaOptimizing Schizophrenia Care: Strategies for Managing Side Effects and Treatment Resistance
Joseph F. Goldberg, MD
- advertisement
Reducing Cortical Lesions in MS with Ocrelizumab: Results from the ORATORI Study
NeuroFrontiersReducing Cortical Lesions in MS with Ocrelizumab: Results from the ORATORI Study
Michael G. Dwyer, PhD
Unraveling the Mechanism: How Ocrelizumab Impacts Cortical Lesions in MS
NeuroFrontiersUnraveling the Mechanism: How Ocrelizumab Impacts Cortical Lesions in MS
Michael G. Dwyer, PhD
Studying Cortical Lesions in MS: Future Research Directions
NeuroFrontiersStudying Cortical Lesions in MS: Future Research Directions
Michael G. Dwyer, PhD
mIDH Gliomas Explained: Characteristics and Management Strategies
NeuroFrontiersmIDH Gliomas Explained: Characteristics and Management Strategies
Jennie Taylor, MD
Climate Change in the Clinic: Examining Neurological Impacts
NeuroFrontiersClimate Change in the Clinic: Examining Neurological Impacts
Beth Ann Malow, MD, MS
From Diagnosis to Treatment: Challenges in Glioblastoma Care
NeuroFrontiersFrom Diagnosis to Treatment: Challenges in Glioblastoma Care
Lauren Schaff, MD
- advertisement
Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data
NeuroFrontiersVorasidenib and mIDH Gliomas: Reviewing the Efficacy Data
Jennie Taylor, MD
Decoding CIDP: Pathogenesis, Diagnosis, and Clinical Clues
On the Frontlines of CIDPDecoding CIDP: Pathogenesis, Diagnosis, and Clinical Clues
Hans Katzberg, MD
Genetics in Schizophrenia Management: Emerging Technological Strategies
On the Frontlines of SchizophreniaGenetics in Schizophrenia Management: Emerging Technological Strategies
Aaron Besterman, MD
